

# Common Infections and Antibiotic Prescribing during the First Year of the COVID-19 Pandemic: A Primary Care-Based Observational Cohort Study

Josi A. Boeijen \*, Alike W. van der Velden, Saskia Hulleger, Tamara N. Platteel, Dorien L. M. Zwart, Roger A. M. J. Damoiseaux, Roderick P. Venekamp and Alma C. van de Pol

Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands; a.w.vandervelden@umcutrecht.nl (A.W.v.d.V.); s.hulleger@umcutrecht.nl (S.H.); T.N.Platteel-3@umcutrecht.nl (T.N.P.); D.Zwart@umcutrecht.nl (D.L.M.Z.); R.A.M.J.Damoiseaux@umcutrecht.nl (R.A.M.J.D.); R.P.Venekamp@umcutrecht.nl (R.P.V.); A.C.vandePol-11@umcutrecht.nl (A.C.v.d.P.)

\* Correspondence: j.a.boeijen@umcutrecht.nl

**Table S1.** Age and sex distribution Julius General Practitioners' Network cohort pre-pandemic and in the first pandemic year.

Age Groups		Male <i>n</i> = (%)	Female <i>n</i> = (%)	Other <i>n</i> = (%)	Total <i>n</i> = (%)
0–12	Pre-pandemic	34,324 (51.0)	32,938 (49.0)	1 (0.0)	67,263 (100)
	Pandemic	34,288 (51.1)	32,870 (48.9)	1 (0.0)	67,159 (100)
13–40	Pre-pandemic	84,519 (47.5)	93,307 (52.5)	3 (0.0)	177,829 (100)
	Pandemic	86,412 (47.6)	95,164 (52.4)	3 (0.0)	181,579 (100)
41–65	Pre-pandemic	63,782 (50.3)	63,137 (49.7)	0 (0.0)	126,919 (100)
	Pandemic	64,598 (50.2)	64,040 (49.7)	0 (0.0)	128,638 (100)
>65	Pre-pandemic	23,895 (45.0)	29,218 (55.0)	1 (0.0)	53,114 (100)
	Pandemic	24,737 (45.2)	30,002 (54.8)	1 (0.0)	54,740 (100)
Unknown Age	Pre-pandemic	4 (100)	0 (0.0)	0 (0.0)	4 (100)
	Pandemic	6 (100)	0 (0.0)	0 (0.0)	6 (100)
Total	Pre-pandemic	206,524 (48.6)	218,600 (51.4)	5 (0.0)	425,129 (100)
	Pandemic	210,041 (48.6)	222,076 (51.4)	5 (0.0)	432,122 (100)


**Table S2.** Age distribution for respiratory/ear, urinary tract, gastrointestinal and skin infection episodes, pre-pandemic and in the first pandemic year.

		Median Age (IQR)	Age Groups				Total
			0–12 <i>n</i> = (%)	13–40 <i>n</i> = (%)	41–65 <i>n</i> = (%)	>65 <i>n</i> = (%)	<i>n</i> = (%)
Respiratory tract/ear	Pre-pandemic	34 (8-56)	20,588 (28.2)	22,209 (30.4)	18,714 (25.6)	11,578 (15.8)	73,089 (100)
	Pandemic	39 (21-57)	10,265 (18.0)	19,695 (34.6)	18,292 (32.2)	8623 (15.2)	56,875 (100)
Urinary tract	Pre-pandemic	50 (29-70)	1608 (6.3)	8837 (34.4)	7252 (28.2)	8006 (31.1)	25,703 (100)
	Pandemic	51 (30-72)	1430 (6.3)	7559 (33.3)	6286 (27.7)	7415 (32.7)	22,690 (100)
Gastrointestinal	Pre-pandemic	31 (8-60)	2910 (29.1)	3069 (30.7)	2018 (20.2)	1993 (19.9)	9990 (100)
	Pandemic	39 (16-66)	1380 (23.5)	1654 (28.2)	1366 (23.3)	1470 (25.0)	5870 (100)
Skin	Pre-pandemic	32 (11-55)	3678 (26.4)	4694 (33.7)	3256 (23.4)	2315 (16.6)	13,943 (100)
	Pandemic	35 (16-59)	2381 (22.5)	3523 (33.3)	2628 (24.8)	2048 (19.4)	10,580 (100)
Total	Pre-pandemic	36 (15-60)	28,784 (23.5)	38,809 (31.6)	31,240 (25.5)	23,892 (19.5)	122,725 (100)
	Pandemic	41 (23-61)	15,456 (16.1)	32,431 (33.8)	28,572 (29.8)	19,556 (20.4)	96,015 (100)


Abbreviations: IQR = interquartile range.

**Table S3.** Sex distribution for respiratory/ear, urinary tract, gastrointestinal and skin infection episodes, pre-pandemic and in the first pandemic year.


		Male <i>n</i> = (%)	Female <i>n</i> = (%)	Other <i>n</i> = (%)	Total <i>n</i> = (%)
Respiratory tract/ear	Pre-pandemic	30,924 (42.3)	42,165 (57.7)	0 (0.0)	73,089 (100)
	Pandemic	24,427 (42.9)	32,447 (57.0)	1 (0.0)	56,875 (100)
Urinary tract	Pre-pandemic	5178 (20.1)	20,525 (79.9)	0 (0.0)	25,703 (100)
	Pandemic	4537 (20.0)	18,153 (80.0)	0 (0.0)	22,690 (100)
Gastrointestinal	Pre-pandemic	4187 (41.9)	5803 (58.1)	0 (0.0)	9990 (100)
	Pandemic	2414 (41.1)	3456 (58.9)	0 (0.0)	5870 (100)
Skin	Pre-pandemic	6777 (48.6)	7165 (51.4)	1 (0.0)	13,943 (100)
	Pandemic	5062 (47.8)	5518 (52.2)	0 (0.0)	10,580 (100)
Total	Pre-pandemic	47,066 (38.4)	75,658 (61.6)	1 (0.0)	122,725 (100)
	Pandemic	36,440 (38.0)	59,574 (62.0)	1 (0.0)	96,015 (100)



(a)




(b)



(c)


**Figure S1.** Macrolide prescription for respiratory infections over time: (a) number of respiratory tract/ear infection episodes over time; (b) number of respiratory tract/ear infection episodes with macrolide prescription over time; (c) antibiotic prescription rate for respiratory tract/ear infections.

## 0-12




(a)

## 13-40




(b)

## 41-65



(c)



(d)

**Figure S2.** Number of respiratory and ear infection episodes and episodes with antibiotic prescription over time per age category: (a) 0–12, (b) 13–40, (c) 41–65, and (d) >65.